Drug Profile


Alternative Names: Chlorpheniramine/hydrocodone/pseudoephedrine - Pernix Therapeutics; Chlorpheniramine/pseudoephedrine/hydrocodone; Hydrocodone/chlorpheniramine/pseudoephedrine; Hydrocodone/pseudoephedrine/chlorpheniramine; Pseudoephedrine/chlorpheniramine/hydrocodone; Pseudoephedrine/hydrocodone/chlorpheniramine; ZUTRIPRO

Latest Information Update: 29 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cypress Pharmaceutical
  • Developer Pernix Therapeutics Holdings
  • Class Antihistamines; Antitussives; Decongestants; Morphinans; Opioid analgesics; Opioid peptides; Propanolamines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists; Histamine H1 receptor antagonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Common cold; Cough; Nasal congestion

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top